Rohini Beavon, United Kingdom
Pfizer Vaccines Medical Development and ScientificPoster Author Of 1 e-Poster
PNEUMOCOCCAL SEROTYPE DISTRIBUTION IN ADULTS HOSPITALIZED WITH RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA IN MALMÖ, SWEDEN
Author Of 2 Presentations
CLINICAL CHARACTERISTICS OF ADULT PNEUMONIA CASES IN THE ERA OF CHILDHOOD PCV13 VACCINATION IN MONGOLIA, 2015-2018 (ID 502)
PNEUMOCOCCAL SEROTYPE DISTRIBUTION IN ADULTS HOSPITALIZED WITH RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA IN MALMÖ, SWEDEN (ID 904)
Abstract
Background
In Sweden, pneumococcal serotype distribution in adults with community-acquired pneumonia (CAP) and potential coverage of licensed and developmental pneumococcal conjugate vaccines (PCVs) are unknown.
Methods
2016-2018, consecutive patients aged ≥18 years hospitalized with chest x-ray positive (CXR+) CAP were enrolled at Skåne University Hospital. Streptococcus pneumoniae (Spn) blood culture isolates were serotyped by multiprime PCR and Quellung reaction. Urine was tested by the pan-pneumococcal urinary antigen test (BinaxNOW®) and Pfizer’s proprietary serotype-specific urine antigen detection assays (UAD1/UAD2). UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in PCV15 and PCV20 plus serotypes 2,9N,17F and 20.
Results
Of 567 enrollees, 518 had CXR+CAP and urine sample collected and were included in analysis. Spn serotypes were identified by UAD or blood culture isolates.
Table CXR+CAP by age group and vaccine serotype categories.
Spn detected: | 18-64 years | ≥65 years | ≥18 years |
PCV13-types* | 12.4% | 10.0% | 10.8% |
PCV15-types* | 13.6% | 12.0% | 12.5% |
PCV20-types* | 20.7% | 15.2% | 17.0% |
Any Spn | 27.2% | 22.9% | 24.3% |
*PCV13:1,3,4,5,6A/6C,6B,7F,9V,14,18C,19A,19F,23F
PCV15:PCV13+22F,33F
PCV20:PCV15+8,10A,11A,12F,15B/C
Conclusions
In the context of robust pediatric PCV immunization, PCV13 serotypes were relatively common in adult CXR+CAP, emphasizing the limits of relying on indirect protection. PCV20 will further increase the ability of direct vaccination to reduce adult pneumonia morbidity.